IDflu

**IDflu** was Sanofi's egg-derived, intradermally administered seasonal **trivalent inactivated split-virion influenza vaccine**. It delivered hemagglutinin antigens from two influenza A strains and one influenza B strain through a pre-filled micro-injection syringe, inducing strain-specific adaptive immune responses and protective anti-influenza antibodies. The seasonal strain composition was updated in accordance with World Health Organization recommendations. IDflu was authorized in the European Union for prophylaxis of influenza in adults, with 9 micrograms per strain historically used in adults through 59 years of age and 15 micrograms per strain used in adults aged 60 years and older. Its European Union marketing authorization was withdrawn on March 19, 2018 at Sanofi Pasteur's request for commercial reasons after the product had not been marketed in the European Union since 2015. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/assessment-report/idflu-epar-public-assessment-report_en.pdf))

Brand names

IDfluIntanza

Other names

influenza vaccine split virion inactivated